Axitinib
- Generic Name
- Axitinib
- Brand Names
- Inlyta, Axitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H18N4OS
- CAS Number
- 319460-85-0
- Unique Ingredient Identifier
- C9LVQ0YUXG
- Background
Axitinib is a second generation tyrosine kinase inhibitor that works by selectively inhibiting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3). Through this mechanism of action, axitinib blocks angiogenesis, tumour growth and metastases. It is reported to exhibit potency that is 50-450 times higher than that of the first generation V...
- Indication
Used in kidney cell cancer and investigated for use/treatment in pancreatic and thyroid cancer.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Advanced Thyroid cancer
- Associated Therapies
- First Line Chemotherapy
Avelumab, Palbociclib and Axitinib in Advanced RCC
- Conditions
- Interventions
- First Posted Date
- 2022-01-04
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Bradley A. McGregor, MD
- Registration Number
- NCT05176288
Strata PATH™ (Precision Indications for Approved Therapies)
- Conditions
- Interventions
- First Posted Date
- 2021-10-28
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Strata Oncology
- Target Recruit Count
- 700
- Registration Number
- NCT05097599
- Locations
- 🇺🇸
Kettering Health Network, Kettering, Ohio, United States
🇺🇸Florida Cancer Specialists - Panhandle, Tallahassee, Florida, United States
🇺🇸Florida Cancer Specialists - North, Saint Petersburg, Florida, United States
Study of Oncolytic Virus in Combination With HX-008 and Axitinib in Melanoma Patients With Liver Metastasis
- First Posted Date
- 2021-10-07
- Last Posted Date
- 2021-10-07
- Lead Sponsor
- Peking University Cancer Hospital & Institute
- Target Recruit Count
- 30
- Registration Number
- NCT05070221
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
- Conditions
- Interventions
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 67
- Registration Number
- NCT05059522
- Locations
- 🇺🇸
Highlands Oncology Group, PA, Springdale, Arkansas, United States
🇷🇺Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary", Omsk, Omskaya Oblast', Russian Federation
🇺🇸MSK Monmouth, Middletown, New Jersey, United States
A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of MK-3475A (Pembrolizumab Formulated With MK-5180) In Advanced Solid Tumors (MK-3475A-C18)
- Conditions
- Interventions
- First Posted Date
- 2021-08-23
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT05017012
- Locations
- 🇨🇱
James Lind Centro de Investigación del Cáncer ( Site 0102), Temuco, Araucania, Chile
🇨🇱FALP-UIDO ( Site 0101), Santiago, Region M. De Santiago, Chile
🇿🇦Cancercare Rondebosch Oncology-Clinical trials ( Site 0055), Rondebosch, Western Cape, South Africa
Current Treatment Outcomes in Japanese RCC Patients Treated With Avelumab Plus Axitinib as First-line Therapy: Retrospective Study (J-DART)
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2023-12-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 48
- Registration Number
- NCT05012865
- Locations
- 🇯🇵
Osaka University Hospital, Suita-city, Osaka, Japan
🇯🇵Jichi Medical University Saitama Medical Center, Saitama City, Saitama, Japan
🇯🇵Kurume University Hospital, Kurume, Fukuoka, Japan
Axitinib + Ipilimumab in Advanced Melanoma
- First Posted Date
- 2021-08-09
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 25
- Registration Number
- NCT04996823
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Pembrolizumab and Axitinib as Neoadjuvant Therapy for Locally Advanced Non-metastatic Clear Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2021-08-06
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 18
- Registration Number
- NCT04995016
- Locations
- 🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China
A Study of Sintilimab in Combination With Axitinib in Advanced Renal Cell Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- Tianjin Medical University Second Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04958473
- Locations
- 🇨🇳
Tianjin Medical Unversity Second Hospital, Tianjin, Tianjin, China
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
- First Posted Date
- 2021-01-05
- Last Posted Date
- 2024-12-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 111
- Registration Number
- NCT04693468
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.